Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Completes Warrant Exercise, Pulling in Additional $17.6M in Proceeds

NEW YORK (GenomeWeb News) – Certain investors have exercised warrants to purchase 12.1 million shares of Vermillion's common stock, providing the company $17.6 million in proceeds, Vermillion said late Thursday.

Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors exercised the warrants, which were issued in conjunction with an equity financing deal that closed in May. The total investment from the deal is about $30.9 million before transaction costs, Vermillion said.

Proceeds will be directed at increasing test sales, improving reimbursements for the company's OVA1 ovarian cancer diagnostic test, expanding commercial opportunities in the US and new markets, and advancing additional next-generation ovarian cancer diagnostic tests.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.